View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

       

News

Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive of $2.4M

🕔9/6/2018 9:18:09 AM 1463

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.4m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) FY18 Results and Business Update

🕔8/30/2018 2:32:07 PM 1259

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to provide an overview of its results for the financial year ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Annual Report 2018

🕔8/30/2018 2:13:22 PM 1193

Your Directors present their report for Regeneus Ltd (ASX:RGS) and its controlled entities for the financial year ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Clinical Trial Results for Cancer Vaccine

🕔7/30/2018 9:45:25 AM 1589

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced positive results from its Phase 1 safety trial of its cancer vaccine which met the primary endpoint of safety and tolerability. The study known as the ACTIVATE trial, is the first clinical trial of RGSH4K, the company's autologous tumour vaccine product for the treatment of solid tumours.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results

🕔7/25/2018 10:00:00 AM 1436

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) US Patent Office to Allow Key Patent for Progenza

🕔7/10/2018 9:01:37 AM 1856

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for issuance of a patent covering the composition and use of Progenza.

Read Full Article

Regeneus Ltd (ASX:RGS) Update on Licensing Progenza in Japan

🕔7/3/2018 10:00:36 AM 1597

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it was on track to complete its clinical collaboration with a Japanese partner for Progenza in Japan in the near-term. The company had disclosed that it anticipated completing the collaboration before the end of 30 June but discussions have taken longer than originally anticipated.

Read Full Article

Regeneus Ltd (ASX:RGS) Grant of ASX Waiver

🕔6/28/2018 11:40:34 AM 1801

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it has entered into an R&D loan facility agreement with Paddington St Finance. The maximum loan value of the facility is the lesser of $2 million or 80% of the estimated refundable tax offset credits under the ATO's R&D tax incentive.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔4/26/2018 9:05:20 AM 2322

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly Report for the period ended 31 March, 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Trial Results of Progenza for Knee Osteoarthritis Published

🕔3/7/2018 10:55:47 AM 3764

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the previously reported positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis have been published in the Journal of Translational Medicine.

Read Full Article
###

92,229 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 203) (Last 30 Days: 794) (Since Published: 42993) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports

Presentations

Research Report

Quarterly Report

Social Media